Therefore, considering all the evidence, we may suppose that GLP-1 RA and SGLT2-i, due to their cardiovascular beneficial effect, can be considered as potential therapeutic tools to positively modify EAT thickness/volume and functional behavior, probably restoring EAT homeostasis even in patients without diabetes. Here, GLP1R is linked to diabetes mellitus.